Literature DB >> 17440070

Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization.

Joel Greshock1, Katherine Nathanson, Anne-Marie Martin, Lin Zhang, George Coukos, Barbara L Weber, Tal Z Zaks.   

Abstract

Tumor-derived cell lines are used as in vitro cancer models, but their ability to accurately reflect the phenotype and genotype of the parental histology remains questionable, given the prevalence of documented cell line-specific cytogenetic changes. We have addressed the issue of whether copy number alterations seen in tumor-derived cell lines reflect those observed in studies of fresh tissue by carrying out a meta-analysis of array-based comparative genomic hybridization data that considers both copy number alteration frequencies and the occurrence of cancer gene amplifications and homozygous deletions. Pairwise correlation comparisons between the data sets of seven diagnosis-specific matched tumor and cell line groups indicate that the trends in aberration frequencies are highly correlated between tumors and cell line sets of matched cancer histology relative to unmatched pairings. Despite their similarities, cell lines showed uniformly higher locus-specific alteration frequencies (P = 0.004) and several recurring cell line-specific alterations emerged. These include the previously documented losses of 13q and 9p and gains of 20q, as well as additional undescribed cell line-specific gains of 5p, 7p, and 17q and losses of 18q and 4q. These results indicate that, on average, cell lines preserve in vitro the genetic aberrations that are unique to the parent histology from which they were derived while acquiring additional locus-specific alterations. These data may enable a more predictive understanding of individual cell lines as in vitro models of cancer biology and therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17440070     DOI: 10.1158/0008-5472.CAN-06-3674

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.

Authors:  Jia Huang; Lin Zhang; Joel Greshock; Theresa A Colligon; Yan Wang; Renee Ward; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Andrew K Godwin; Joseph R Testa; Katherine L Nathanson; Phyllis A Gimotty; George Coukos; Barbara L Weber; Yan Degenhardt
Journal:  Genes Chromosomes Cancer       Date:  2011-05-11       Impact factor: 5.006

2.  (Cyto)genomic and epigenetic characterization of BICR 10 cell line and three new established primary human head and neck squamous cell carcinoma cultures.

Authors:  Ilda P Ribeiro; Joana M Rodrigues; Alexandra Mascarenhas; Vanessa Marques; Francisco Caramelo; Maria J Julião; Thomas Liehr; Joana B Melo; Isabel M Carreira
Journal:  Genes Genomics       Date:  2019-07-18       Impact factor: 1.839

3.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.

Authors:  Nuo Yang; Sippy Kaur; Stefano Volinia; Joel Greshock; Heini Lassus; Kosei Hasegawa; Shun Liang; Arto Leminen; Shan Deng; Lori Smith; Cameron N Johnstone; Xian-Ming Chen; Chang-Gong Liu; Qihong Huang; Dionyssios Katsaros; George Adrian Calin; Barbara L Weber; Ralf Bützow; Carlo M Croce; George Coukos; Lin Zhang
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

4.  PhenomiR: a knowledgebase for microRNA expression in diseases and biological processes.

Authors:  Andreas Ruepp; Andreas Kowarsch; Daniel Schmidl; Felix Buggenthin; Barbara Brauner; Irmtraud Dunger; Gisela Fobo; Goar Frishman; Corinna Montrone; Fabian J Theis
Journal:  Genome Biol       Date:  2010-01-20       Impact factor: 13.583

5.  Identifying master regulators of cancer and their downstream targets by integrating genomic and epigenomic features.

Authors:  Olivier Gevaert; Sylvia Plevritis
Journal:  Pac Symp Biocomput       Date:  2013

6.  High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma.

Authors:  Saloua Toujani; Philippe Dessen; Nathalie Ithzar; Gisèle Danglot; Catherine Richon; Yegor Vassetzky; Thomas Robert; Vladimir Lazar; Jacques Bosq; Lydie Da Costa; Christine Pérot; Vincent Ribrag; Catherine Patte; Jöelle Wiels; Alain Bernheim
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

7.  Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

Authors:  Martin L Sos; Kathrin Michel; Thomas Zander; Jonathan Weiss; Peter Frommolt; Martin Peifer; Danan Li; Roland Ullrich; Mirjam Koker; Florian Fischer; Takeshi Shimamura; Daniel Rauh; Craig Mermel; Stefanie Fischer; Isabel Stückrath; Stefanie Heynck; Rameen Beroukhim; William Lin; Wendy Winckler; Kinjal Shah; Thomas LaFramboise; Whei F Moriarty; Megan Hanna; Laura Tolosi; Jörg Rahnenführer; Roel Verhaak; Derek Chiang; Gad Getz; Martin Hellmich; Jürgen Wolf; Luc Girard; Michael Peyton; Barbara A Weir; Tzu-Hsiu Chen; Heidi Greulich; Jordi Barretina; Geoffrey I Shapiro; Levi A Garraway; Adi F Gazdar; John D Minna; Matthew Meyerson; Kwok-Kin Wong; Roman K Thomas
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

8.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Authors:  Keiran S M Smalley; Mercedes Lioni; Maurizia Dalla Palma; Min Xiao; Brijal Desai; Suzanne Egyhazi; Johan Hansson; Hong Wu; Alastair J King; Patricia Van Belle; David E Elder; Keith T Flaherty; Meenhard Herlyn; Katherine L Nathanson
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

9.  Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines.

Authors:  J Greshock; K Nathanson; A Medina; M R Ward; M Herlyn; B L Weber; T Z Zaks
Journal:  Genes Chromosomes Cancer       Date:  2009-05       Impact factor: 5.006

10.  Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Authors:  Katumi Tsuji; Shigeto Kawauchi; Soichiro Saito; Tomoko Furuya; Kenzo Ikemoto; Motonao Nakao; Shigeru Yamamoto; Masaaki Oka; Takashi Hirano; Kohsuke Sasaki
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.